Why the study?
Despite advances in cardiovascular treatments, the burden of cardiovascular disease remains high, highlighting a need for new therapeutic targets such as lipoprotein (a).
This narrative review highlights Lipoprotein (a) as a potential novel target for cardiovascular disease prevention and discusses current and investigational treatments.
Lp(a) merits evaluation as a residual risk target; leaves open whether specific lowering therapies improve outcomes in trials.
Advances in several fields of cardiovascular (CV) medicine have produced new treatments (e.g. to treat dyslipidaemia) that have proven efficacy in terms of reducing deaths and providing a better quality of life. However, the burden of CV disease (CVD) remains high. Thus, there is a need to search for new treatment targets. Lipoprotein (a) [Lp(a)] has emerged as a potential novel target since there is evidence that it contributes to CVD events. In this narrative review, we present the current evidence of the potential causal relationship between Lp(a) and CVD and discuss the likely magnitude of Lp(a) lowering required to produce a clinical benefit. We also consider current and investigational treatments targeting Lp(a), along with the potential cost of these interventions.
No takes yet. Share an insight, caveat, or question.
Parthymos et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: